Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to $7.5 million.

  • Editas Medicine's Change in Receivables rose 649152.54% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year increase of 44860.63%. This contributed to the annual value of $6.1 million for FY2024, which is 2056.72% up from last year.
  • Latest data reveals that Editas Medicine reported Change in Receivables of $7.5 million as of Q3 2025, which was up 649152.54% from $78000.0 recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Change in Receivables registered a high of $16.1 million during Q4 2024, and its lowest value of -$15.8 million during Q1 2025.
  • Moreover, its 5-year median value for Change in Receivables was -$1000.0 (2024), whereas its average is $109578.9.
  • Its Change in Receivables has fluctuated over the past 5 years, first crashed by 113333.33% in 2021, then soared by 3130625.0% in 2022.
  • Editas Medicine's Change in Receivables (Quarter) stood at $16000.0 in 2021, then surged by 31306.25% to $5.0 million in 2022, then skyrocketed by 54.53% to $7.8 million in 2023, then soared by 107.86% to $16.1 million in 2024, then tumbled by 53.27% to $7.5 million in 2025.
  • Its Change in Receivables was $7.5 million in Q3 2025, compared to $78000.0 in Q2 2025 and -$15.8 million in Q1 2025.